Nal-Iri and 5-FU/LV Compared to 5-FU/LV in Patients with Cholangio- and Gallbladder Carcinoma Previously Treated with Gemcitabine-Based Therapies: The AIO NALIRICC Trial
Arndt Vogel(Princess Margaret Cancer Centre), Martha M. Kirstein(University of Lübeck), Sebastian Belle(Heidelberg University), Gunnar Folprecht, Anna Saborowski(Medizinische Hochschule Hannover), Lutz Jacobasch(Orthopädische Praxis), Nicolas Ziegenhagen, Daniel Pink(Universitätsmedizin Greifswald), P. Schuett(Oncoceutics (United States)), Johannes Mohm(University Hospital Carl Gustav Carus), Ullrich Graeven(Kliniken Maria Hilf), C. Lerchenmueller(HOPE Clinic), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Stephan Kanzler(Leopoldina Krankenhaus Schweinfurt), Henning Wege(Universität Hamburg), Albrecht Kretzschmar(Roche (Switzerland)), Eray Goekkurt(Sorbonne Université), Stefan Böck(Ludwig-Maximilians-Universität München), Patrick Wenzel(TUM Klinikum)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k